Clinical trials
Ovarian Neoplasms trials in Poland
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
93 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 5 |
| 2006 | 3 |
| 2007 | 2 |
| 2008 | 3 |
| 2009 | 3 |
| 2010 | 4 |
| 2011 | 3 |
| 2013 | 9 |
| 2014 | 3 |
| 2015 | 4 |
| 2016 | 4 |
| 2017 | 5 |
| 2018 | 3 |
| 2019 | 3 |
| 2020 | 4 |
| 2021 | 8 |
| 2022 | 8 |
| 2023 | 2 |
| 2024 | 4 |
| 2025 | 7 |
| 2026 | 5 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 45 |
| Recruiting | 18 |
| Active, not recruiting | 15 |
| Terminated | 11 |
| Unknown status | 3 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AstraZeneca | 13 |
| Merck Sharp & Dohme LLC | 6 |
| Amgen | 4 |
| Hoffmann-La Roche | 4 |
| Daiichi Sankyo | 3 |
| EMD Serono Research & Development Institute, Inc. | 3 |
| Eli Lilly and Company | 3 |
| Genmab | 3 |
| Pfizer | 3 |
| SOTIO a.s. | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Ovarian Neoplasms | 93 |
| Fallopian Tube Neoplasms | 21 |
| Endometrial Neoplasms | 13 |
| Breast Neoplasms | 12 |
| Carcinoma, Ovarian Epithelial | 12 |
| Colorectal Neoplasms | 11 |
| Neoplasms | 11 |
| Peritoneal Neoplasms | 11 |
| Carcinoma, Non-Small-Cell Lung | 8 |
| Pancreatic Neoplasms | 7 |
Trials
Showing 76 to 93 of 93. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.